Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial

Dickran Kazandjian^*, Neha Korde, Sham Mailankody, Elizabeth Hill, William D. Figg, Mark Roschewski, Ola Landgren

^*Corresponding author for this work

Research output: Contribution to journal › Letter › peer-review